For the treatment of cutaneous T-cell lymphoma (CTCL), venetoclax showed potential as an oral therapeutic option for CTCL patients with blood involvement [77], and the combination of venetoclax with histone deacetylase (HDAC) inhibition offered synergistic killing effects on patient-derived CTCL cells [78]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.